Severe community-acquired pneumonia

Current Opinion in Critical Care

Volumn 8, Issue 5, 2002, Pages 453-460

  Ewig, Santiago ^a   Torres, Antoni ^b  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACINETOBACTER; CHRONIC OBSTRUCTIVE LUNG DISEASE; DIAGNOSTIC APPROACH ROUTE; HUMAN; PNEUMONIA; POSITIVE END EXPIRATORY PRESSURE; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE; REVIEW;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; HUMANS; PNEUMONIA, BACTERIAL; PRACTICE GUIDELINES; PROGNOSIS; RESPIRATION, ARTIFICIAL;

EID: 0036790034     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/00075198-200210000-00014     Document Type: Review

References (59)

1. Niederman MS, Bass JB Jr, Campbell GD, et al.: Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 1993, 148:1418-1426.
2. Ewig S, Ruiz M, Mensa J, et al.: Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998, 158:1102-1108.
3. Fine MJ, Auble TE, Yealy DM, et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
4. Ewig S, Seifert K, Kleinfeld T, et al.: Management of patients with community-acquired pneumonia in a primary care hospital: a critical evaluation. Respir Med 2000, 94:556-563.
5. Roson B, Carratala J, Dorca J, et al.: Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001, 33:158-165.
6. Niederman MS, Mandell LA, Anzueto A, et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
7. Community-acquired pneumonia in adults in British hospitals in 1982-1983: a survey of aetiology, mortality, prognostic factors and outcome. British Thoracic Society and the Public Health Laboratory Service. Q J Med 1987, 239:195-220.
8. BTS Guidelines for the Management of Community Acquired Pneumonia in Adults. Thorax 2001, 56(suppl 4):IV1-IV64.
9. Levin KP, Hanusa BH, Rotondi A, et al.: Arterial blood gas and pulse oximetry in initial management of patients with community-acquired pneumonia. J Gen Intern Med 2001, 16:590-598.
10. Vegelin AL, Bissumbhar P, Joore JCA, et al.: Guidelines for severe community acquired pneumonia in the western world. Neth J Med 1999, 55:110-117.
11. Feldman C, Viljoen E, Morar R, et al.: Prognostic factors in severe community-acquired pneumonia in patients without co-morbid illness. Respirology 2001, 6:323-330.
12. Gowardman J, Trent L: Severe community-acquired pneumonia: a one-year analysis in a tertiary referral intensive care unit. N Z Med J 2000, 113:161-164.
13. Marik PE: The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000, 15:85-90.
14. Ewig S, Torres A: Severe community-acquired pneumonia. Clin Chest Med. 1999, 20:575-587.
15. Bartlett JG, Breiman RF, Mandell LA, et al.: Community-acquired pneumonia in adults: guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998, 26:811-838.
16. Huchon G, Woodhead M: Management of adult community-acquired lower respiratory tract infections. Eur Respir Rev 1998, 8:391-426.
17. Park DR, Sherbin VL, Goodman MS, et al.: The etiology of community acquired pneumonia at an urban public hospital: influence of human immuno-deficiency virus infection and initial severity of illness. J Infect Dis 2001, 184:268-277.
18. Chen MZ, Hsueh PR, Lee LN, et al.: Severe community-acquired pneumonia due to Acinetobacter baumannii. Chest 2001, 120:1072-1077.
19. Wunderink RG, Waterer GW: Severe community acquired pneumonia. The need to customize empiric therapy. Chest 2001, 120:1053-1054.
20. Birch C, Gowardman J: Streptococcus pyogenes: a forgotten cause of severe community-acquired pneumonia. Anaesth Intensive Care 2000, 28:87-90.
21. Waterer GW, Quasney MW, Cantor RM, et al.: Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 2001, 163:1599-1604.
22. Rodriguez RM, Fancher ML, Phelps M, et al.: An emergency department-based randomized trial of nonbronchoscopic bronchoalveolar lavage for early pathogen identification in severe community acquired pneumonia. Ann Emerg Med 2001, 38:357-363.
23. Ewig S, Torres A: Flexible bronchoscopy for nosocomial pneumonia. Clin Chest Med 2000, 22:263-279.
24. Murdoch DR, Laing RT, Mills GD, et al.: Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001, 39:3495-2498.
25. Formica N, Yates M, 13eers M, et al.: The impact of diagnosis by legionella urinary antigen test on the epidemiology and outcomes of Legionnaires' disease. Epidemiol Infect 2001, 127:275-280.
26. McAvin JC, Reilly PA, Roudabush RM, et al.: Sensitive and specific method for rapid identification of Streptococcus pneumoniae using real-time fluorescence PCR. J Clin Microbiol 2001, 39:3446-3451.
27. Tang C, Macfarlane JT: Early management of younger adults dying of community acquired pneumonia. Respir Med 1993, 87:289-294.
28. Dedier J, Singer DE, Chang Y, et al.: Processes of care, illness severity, and outcomes in the management of community-acquired pneumonia at academic hospitals. Arch Intern Med 2001, 161:2099-2104.
29. Dean NC, Silver MP, Bateman KA, et al.: Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001, 110:451-457.
30. Malone DC, Shaban HM: Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001, 35:1180-1185.
31. Hirani NA, MacFarlane JT: Impact of management guidelines on the outcome of severe community-acquired pneumonia. Thorax 1997, 52:17-21.
32. Nathwani D, Williams F, Winter J, et al.: Use of indicators to evaluate the quality of community-acquired pneumonia management. Clin Infect Dis 2002, 34:318-323.
33. Niederman MS: Can guidelines for the treatment of respiratory infections lead to reduced rates of antibiotic resistance? Semin Respir Infect 2001, 16:203-209.
34. Ball P, Baquero F, Cars O, et al.: Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002, 49:31-40.
35. Thornsberry C, Sahm DF, Kelly LJ, et al.: Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. Clin Infect Dis 2002, 34(suppl 1): S4-S16.
36. Reinert RR, Al-Lahham A, Lempede M, et al.: Emergence of macrolide and penicillin resistance among invasive pneumococcal isolates in Germany. J Antimicrob Chemother 2002, 49:61-68.
37. Hyde TB, Gay K, Stephens DS, et al.: Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286:1857-1862.
38. Pallares R, Linares J, Vadillo M, et al.: Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med 1995, 333:474-480.
39. Ewig S, Ruiz M, Torres A, et al.: Pneumonia acquired in the community through drug resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999, 159:1835-1842.
40. Metlay JP, Hofmann J, Cetron MS, et al.: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000, 30:520-528.
41. File TM Jr: Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of beta-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 34(suppl 1):S17-S26.
42. Moroney JF, Fiore AE, Harrison LH, et al.: Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001, 33:797-805.
43. Roson B, Carratala J, Tubau F, et al.: Usefulness of betalactam therapy for community-acquired pneumonia in the era of drug-resistant Streptococcus pneumoniae: a randomized study of amoxicillin-clavulanate and ceftriaxone. Microb Drug Resist 2001, 7:85-96.
44. Feikin DR, Schuchat A, Kolczak M, et al.: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000, 90:223-229.
45. Heffelfinger JD, Dowell SF, Jorgensen JH, et al.: Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000, 160:1399-1408.
46. Lynch III JP, Martinez FJ: Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002, 34(suppl 1):S27-S46.
47. th International Conference on the Macrolides, Azalides, Streptogramins, and Ketolides (Barcelona, Spain) 1998.
48. Fogarty C, Goldschmidt R, Bush K: Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin Infect Dis 2000, 31:613-615.
49. Kelley MA, Weber DJ, Gilligan P, et al.: Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000, 31:1008-1011.
50. Waterer GW, Somes GW, Wunderink RG: Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001, 161:1837-1842.
51. Resistance of Streptococcus pneumoniae to fluoroquinolones-United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001, 50:800-804.
52. Davidson R, Cavalcanti R, Brunton JL, et al.: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:747-750.
53. Empey PE, Jennings HR, Thornton AC, et al.: Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001, 35:687-690.
54. Castro-Guardiola A, Viejo-Rodriguez L, Soler-Simon S, et al.: Efficacy and safety of oral and early switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001, 111:367-374.
55. Antonelli M, Conti G, Rocco M, et al.: A comparison of noninvasive positive airway pressure by face mask and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998, 339:429-435.
56. Confalonieri M, Potenta A, Carbone G, et al.: acute respiratory failure in patients with severe community acquired pneumonia. Am J Respir Crit Care Med 1999, 160:1585-1591.
57. Jolliet P, Abajo B, Pasquina P, et al.: Non-invasive pressure support ventilation in severe community-acquired pneumonia. Intensive Care Med 2001, 27:812-821.
58. Hill NS: Noninvasive ventilation routine therapy for community-acquired pneumonia? Not so fast! Intensive Care Med 2001, 27:797-799.
59. Woodhead MA, Macfarlane JT, Rodgers FG, et al.: Etiology and outcome of severe community-acquired pneumonia. J Infect 1985, 10:204-210.